Biomarker Tests for Molecularly Targeted Therapies

Print

The Key to Unlocking Precision Medicine NEJM

 

An IOM committee focused on biomarkers for molecularly targeted therapies has issued recommendations about regulatory, reimbursement, and clinical practice issues, in order to guide precision medicine in advancing the care of patients with cancer and other diseases.

This article was published on June 1, 2016, at NEJM.org. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

SOURCE INFORMATION

From the Fred Hutchinson Cancer Research Center and the University of Washington — both in Seattle (G.H.L.); the Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, National Academies of Sciences, Engineering, and Medicine, Washington, DC (G.H.L., H.L.M.); and Vanderbilt University, Nashville (H.L.M.).

Access this article: Subscribe to NEJM | Purchase this article


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Gene Therapy Left / Biomarker Tests for Molecularly Targeted Therapies